Evotec Phase 1 Orthopoxvirus Antibody Trial
Analysis based on 7 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026
The announcement highlights Evotec's capabilities in biodefense and continuous biologics manufacturing, potentially strengthening its position for future government contracts. The news may positively influence investor sentiment for Evotec, though the financial impact is modest given the early-stage nature of the program.
Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Evotec — Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program. The trial is a first-in-human study evaluating the prophylactic therapy intended to protect warfighters from biological threats such as smallpox and mpox. Manufacturing of clinical trial material was completed at the J.POD facility in Redmond, Washington, using continuous bioprocessing. This milestone fulfills the scope of a 2023 contract with the U.S. Department of War, which, together with an earlier 2022 plague antibody contract, has a combined potential value of up to $123.9 million. The program demonstrates the scalability of Evotec — Just – Evotec Biologics' continuous manufacturing platform for biodefense preparedness.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard